CME Credit Hours: 1.25
Neoadjuvant therapy has been a well-established component of rectal cancer treatment. Increasing understanding of the heterogeneity of rectal cancer has led to the recognition that a one-size-fits-all neoadjuvant regimen is suboptimal. Recently, a variety of neoadjuvant regimens have been investigated. This symposium will provide surgeons with a comprehensive understanding of the oncologic outcomes and toxicity profiles associated with the various regimens and to provide a framework for tailoring neoadjuvant therapy to an individual patient’s tumor.
Objectives
At the conclusion of this session, participants should be able to:
- Recognize radiographic features that correlate with favorable vs. unfavorable prognosis
- Describe the key distinguishing features associated with short vs. long course pelvic radiation
- Explain the different neoadjuvant chemotherapy regimens and their side effects
Co-Directors
Y. Nancy You, MD, Houston, TX
Matthew Silviera, MD, St. Louis, MO
Introduction- Defining the Goal and Understanding the Trade-offs
Y. Nancy You, MD, Houston, TX
Tools for Risk Stratifying Rectal Cancers
Marc Gollub, MD, New York, NY
Radiation: When is Less More
Bashar Safar, MD, Baltimore, MD
Chemotherapy: Options and Outcomes
Maria Widmar, MD, MPH, New York, NY
Putting it All Together: Matching the Tool with the Goal
Eric Dozois, MD, Rochester, NY
Case Presentation and Question and Answer
Matthew Silviera, MD, St. Louis, MO
Adjourn